Japan's Taisho buys select Asian assets from Bristol-Myers

Japanese firm Taisho Pharmaceutical pays $310 million for six Asia-Pacific brands and the Indonesian business of Bristol-Myers, as it seeks to build its presence in the OTC drug market.

Japan's Taisho Pharmaceutical will buy six Asia-Pacific brands and the Indonesian subsidiary of Bristol-Myers Squibb for $310 million, according to an announcement yesterday. It is paying $160 million for the brands and $150 million for the Indonesian company.

Taisho is acquiring the trademarks, product registrations and websites for Tempra, a fever-reducing medicine, Counterpain, an anti-inflammatory analgesic for application, and four other brands. Tempra is well-established in Indonesia and the Philippines, while Counterpain has a large share of the market...

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition


  • 2nd Compliance Summit Southeast Asia

    17 August 2017  |  Singapore
    The 2017 Compliance Summit Southeast Asia will take an in-depth look at the key compliance considerations today with a focus on regulation and new ...